HER2 plays an important role in cell growth and survival, but many cancers, including gastroesophageal adenocarcinoma (GEA), can overexpress this protein, leading to uncontrolled cell growth and impacting prognosis. While not everyone diagnosed with a GEA will be HER2-positive, it is helpful to test for HER2 as the presence of this protein can help inform the treatment approach. As a long-time leader in sleep medicine, we have come to understand the importance of providing solutions that address patients’ lives holistically, especially for those living with serious, debilitating rare disorders. Read more about how we’re delivering on this promise and supporting the sleep community at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies. As we continue to make advancements in cancer research, we’re focused on delivering treatment options in areas of oncology with high unmet needs, including HER2-positive biliary tract cancer (BTC), as well as supporting patient communities beyond R&D. Through recent advocacy efforts, in addition to sharing new data at the upcoming ASCO 2024 Annual Meeting, we’re committed to supporting patients throughout their disease journeys.
Transforming Lives.
Redefining Possibilities.
Science Stories
The Potential of HER2-Targeted Therapies in Gastroesophageal Adenocarcinoma
Perspectives
SLEEP 2024: How We’re Pioneering Research for the Sleep Community
Perspectives
A Commitment to Advancing Science for Biliary Tract Cancer Patients
News and Events
Jun 20, 2024
Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.
Living Our Values
Clinical Trials
By unlocking biopharmaceutical discoveries to develop novel medicines, we are giving thousands of people around the world the opportunity to redefine what’s possible.